Found 30 matching trials
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension PHASE2 The purpose of this study is to determine the blood pressure lowering respo...
Show More Location
Multiple Locations
Treatments Being Tested
Candesartan cilexetil (Atacand), 4 mg Candesartan cilexetil (Atacand), 8 mg Nifedipine GITS (Adalat, BAYA1040), 20 mg Nifedipine GITS (Adalat, BAYA1040), 30 mg Nifedipine GITS (Adalat, BAYA1040), 60 mg Placebo Candesartan cilexetil (Atacand), 16 mg Candesartan cilexetil (Atacand), 32 mg Learn More & Join Trial
Recurrent Stroke Prevention Clinical Outcome Study PHASE4 1. Objectives and Hypothesis
1. Objectives:
This study evaluates...
Show More Location
Jichi Medical Univercity
Learn More & Join Trial
Precision Treatment With Angiotensin Converting Enzyme Inhibitor PHASE4 Angiotensin converting enzyme inhibitors (ACEI) are the first-line treatmen...
Show More Location
Yonsei University Health System, Severance Hospital
Learn More & Join Trial
Genetic Epidemiology of Responses to Antihypertensives N/A To determine whether measured variation in genes coding for components of v...
Show More Learn More & Join Trial
Candesartan Effect in Second Stage Arterial Hypertension PHASE4 To compare the changes in mean sitting DBP from baseline after 4 weeks of t...
Show More Learn More & Join Trial
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo PHASE3 The aim is to compare the blood pressure lowering effect of the combination...
Show More Learn More & Join Trial
A Pharmacogenomic Study of Candesartan in Heart Failure PHASE4 The purpose of this study is to evaluate the impact of genetic variations o...
Show More Location
Montreal Heart Institute
Learn More & Join Trial
Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial PHASE4 Candesartan is effective in preventing cardiovascular events in patients wi...
Show More Location
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
Learn More & Join Trial
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia PHASE3 REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform tria...
Show More Location
University of Florida
Learn More & Join Trial
An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension PHASE3 The purpose of this study is to evaluate the efficacy and safety of TCV-116...
Show More Learn More & Join Trial